In Silico Structure-Guided Design of Peptide Candidates Targeting γ-Secretase Subunit Assembly.
Peptide researchers just got a new playbook for tackling γ-secretase, an enzyme complex with its fingerprints all over Alzheimer’s disease and certain cancers. Instead of going after the enzyme’s active site—the usual move, but a strategy loaded with side effects—scientists from Istanbul used structure-guided in silico design to target the assembly process itself. Translation: they’re using peptides to jam the gears, not just block the blade.
Proteins
by Yuka SA, Telli K, Yılmaz A
“In Silico Structure-Guided Design of Peptide Candidates Targeting γ-Secretase Subunit Assembly. Yuka SA(1)(2), Telli K(3), Yılmaz A(4). Author information: (1)Department of Bioengineering, Yildiz Technical University, Istanbul, Turkey. (2)Health Biotechnology Joint Research and Application Center of Excellence, İstanbul, Turkey. (3)Department of Molecular Biology and Genetics, Istanbul Kultur University, Istanbul, Turkey. (4)Department of Molecular Biology and Genetics, Yildiz Technical University, Istanbul, Turkey. The γ-secretase complex is a membrane-embedded protease essential for intramembrane cleavage of substrates such as Notch receptors and the amyloid precursor protein (APP), processes central to cancer progression and Alzheimer's disease (AD) pathology. However, catalytic inhibition of γ-secretase disrupts multiple signaling pathways, resulting in dose-limiting toxicities. In this study, we report a structure-guided approach to generate peptides with binding and stability profiles that disrupt the assembly of γ-secretase by targeting the interactions of Presenilin-1 and Nicastrin with APH1. First, molecular docking was performed for 36 248 peptides of varying lengths to assess their affinity scores to the PS1 and NCT interaction regions of APH1. Peptides filtered based on their affinity scores and physicochemical properties were then subjected to global molecular docking. 50-nanosecond molecular dynamics simulations and MM/PBSA analyses were performed on the top 10 potential candidates, identifying those with high dynamic interaction potential. Thus, seven γ-secretase inhibitor candidates with favorable affinity scores capable of providing stable interactions and thereby having the potential to disrupt the APH1:PS1 assembly were identified. This approach, which overcomes the challenges of targeting the transmembrane catalytic domain, is based on the inhibition of subunit assembly and presents promising candidates for future experimental studies. © 2026 The Author(s). PROTEINS: Structure, Function, and Bioinformatics published by Wiley Periodicals LLC.”
Here’s how it went down. The team screened over 36,000 peptide sequences, using computational docking to see which ones could best elbow into the interaction zones between γ-secretase subunits—specifically the Presenilin-1 and Nicastrin regions that interface with APH1. Only the top binders (and the ones with solid, research-friendly stability) made the cut for deeper molecular dynamics simulations.
What’s cool:
Out of tens of thousands, seven peptide candidates showed standout binding and stability in simulations.
Instead of risking system-wide disruption, these peptides aim to selectively mess with subunit assembly.
This opens the door to new ways of modulating γ-secretase for research—without the nasty off-target effects that come with old-school inhibitors.
The approach sidesteps the classic headaches of targeting transmembrane enzymes. Rather than brute force inhibition, it’s precision disruption at the protein–protein interaction level. If these peptides hold up in wet-lab studies, researchers could have brand-new tools to probe Alzheimer’s mechanisms—or even run interference on cancer-linked pathways.
Key takeaway: in silico screening is making it possible to tailor peptides for complex intracellular targets that used to be off-limits. For the latest on peptide design techniques and candidate discoveries, check the peptide research index.
No dull moments in computational peptide research—just smarter ways to ask better questions.
Related Reading
Eu(3+)-mediated dual-crosslinked collagen-mimetic peptide/sodium alginate hydrogel for 3D-printed skin wound dressings.
News · Acta BiomaterAntimicrobial-potentiated colorectal cancer therapy with synchronized tumoricidal immunity via a self-deliverable nanopeptide.
News · J Am Pharm Assoc (2003)Real-world weight impact upon tirzepatide discontinuation at a single-center endocrinology clinic in patients with overweight or obesity.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.